Business Wire

Wolters Kluwer Launches AI-enhanced UpToDate Enterprise Edition in EMEA

Share

Wolters Kluwer Health today announced its UpToDate® Enterprise Edition will be available to healthcare systems and hospitals in the Europe, Middle East, and Africa (EMEA) region beginning in Q3. Designed specifically for large healthcare systems and hospitals, the clinical decision support (CDS) solution, which features AI enhancements, is designed to support healthcare administrators and clinicians to help deliver consistently high-quality care. Wolters Kluwer Health will demonstrate the solution at HIMSS25 Europe in Paris, June 10-12, 2025.

“Leveraging AI technology, UpToDate Enterprise Edition goes beyond traditional decision support to provide unparalleled quality that supports streamlined, integrated workflows and faster time-to-answers, ultimately fostering patient engagement and transforming care delivery,” said Christian Cella, Vice President, International Segment for Clinical Effectiveness at Wolters Kluwer Health. “With UpToDate Enterprise becoming available in EMEA, we are extending Wolters Kluwer’s commitment to enhancing clinical decision-making worldwide.”

For decades, healthcare professionals around the world have trusted UpToDate clinical decision support to enable confident decision-making and reduce variability in care. The UpToDate Enterprise Edition solution builds on that value to include advanced features, insights, and technology innovations to help them meet these current and emerging industry challenges. The solution is in early release at 40 of the largest health systems in EMEA joining the over 350 health systems in North America using the UpToDate Enterprise Edition.

“UpToDate has been an extremely valuable clinical decision support resource for Icelandic health institutions. UpToDate Enterprise Edition adds new features including AI that will aid our staff to make smarter clinical decisions to further help improve patient care,” says Runólfur Pálsson, CEO of Landspítali University Hospital and Professor of Medicine at the Faculty of Medicine of the University of Iceland.

UpToDate Enterprise Edition offers harmonized content and solutions for the entire care team, empowering them to make more informed, confident, and impactful decisions. With its AI-Enhanced Search capabilities, clinicians can now experience the efficiency of receiving highly focused verbatim answers from a market leading clinical decision solution using natural language queries—a time-saver for busy healthcare professionals. The AI-powered Analytics Dashboard offers healthcare organizations the ability to harness valuable organizational data for improved efficiency and educational opportunities.

“Deploying UpToDate Enterprise Edition is an important initiative in supporting our digital innovation strategy,” said Professor Adrian Harris, Chief Medical Officer at the Royal Devon University Healthcare NHS Foundation Trust. “By leveraging the data, analytics and AI capabilities now available within UpToDate, we can further support medical education and optimize clinical decision making, helping us deliver the best possible care for all patients and enabling our local population to stay well.”

This enhanced solution unifies care teams and administrators with a focus on workflow innovation, analytics, and advanced care features. With access across teams, organizations can:

  • Manage complexity by advancing clinical decisions
  • Enhance satisfaction and collaboration by aligning all members of the care team to the same trusted UpToDate content with advanced decision-making features
  • Help alleviate burnout through improved workflow capabilities
  • Improve resource utilization and business outcomes via system-wide data and insights and self-service analytics, such as system-wide topic usage, UpToDate topic benchmarking, and CME accreditation activity.

In the Frost Radar™: Clinical Decision Support System, 2025report, Wolters Kluwer was the only one named both a “Company to Action” and the market leader for innovation. Frost & Sullivan screened and analyzed more than 60 clinical decision support vendors across point-of-care segments and short-listed 10 companies based on a detailed analysis of their corporate growth potential and ability to drive visionary innovation in this space.

Learn more about UpToDate Enterprise Edition in EMEA.

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250604785080/en/

Contacts

Media Contact
Suzanne Moran
Associate Director, External Communications
Health
Wolters Kluwer
Office/Mobile: +1 6178938586
Suzanne.Moran@Wolterskluwer.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn

Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release

Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of

500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release

500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa

Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release

Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la

Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release

Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye